LUCD · Lucid Diagnostics Inc.
$0.75
-0.06 (-7.17%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$167.88M
Shares
203.24M
Volume · Sep 30
1.78M
Avg daily vol (3M)
1.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.75
Open$0.82
Day$0.74–0.82
52W close$0.75–1.47
Avg vol 30d1.1M
Short int12.8M · 6.3% float · 12.5d
Short vol65%
Last earningsAug 13, 2026
DataOct 2021–Sep 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 6 wks
filed Aug 12, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.45M
Trailing 12 months
Net income (TTM)
−$52.26M
Trailing 12 months
Revenue growth YoY
+26.7%
Year over year
Operating margin
-930.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+114.7%
Year over year · more shares
Price change (1Y)
-21.5%
Trailing year
Short interest
6.3%
Latest settlement · 12.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−18%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−35%
trailing
YTD return
−31%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.31% of float · ▲ +7.9% MoM · 12.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
116 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+79%
Y/Y
Gross margin
9%
contracting
EPS growth
+17%
Y/Y
Free cash flow
$-46.7M
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.31% of float · ▲ +7.9% MoM · 12.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
116 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $1
vs 200-day avg -31%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EBITDA non-GAAP | -$11.54M | the three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) as reported -11.69M
+224K Depreciation and amortization expense
-73K Interest expense, net
= EBITDA -11.54M
|
|||
| Net operating expenses non-GAAP | $12.33M | the three months ended June 30, 2026 | — |
| Non-GAAP adjusted (loss) non-GAAP | -$10.85M | the three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA -11.54M
+1.69M Stock-based compensation expense
+29K Operating expenses issued in stock
-1.04M Change in FV convertible debt
= Non-GAAP adjusted (loss) -10.85M
|
|||
| Non-GAAP adjusted (loss) income per share non-GAAP | -$0.06 | the three months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUCD
this stock
Lucid Diagnostics Inc.
|
$167.88M | -31.1% | +79.0% | — | 6.3% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUCD | -10.5% | -22.9% | -34.7% | -23.3% | -31.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -9.8% | -23.0% | -46.9% | -22.7% | -42.9% |